Sogani P C, Whitmore W F
Cancer Treat Res. 1988;39:131-45. doi: 10.1007/978-1-4613-1731-9_9.
The various clinical trials suggest that the qualitative and quantitative responses of patients with Stage D prostatic carcinoma to antiandrogens are similar to those achieved with conventional endocrine therapy. These antiandrogens appear generally safe and many avoid the increased risks of cardiovascular or thromboembolic complications seen with estrogen therapy. Further, flutamide appears to have a lesser adverse effect on libido and sexual potency than do alternative therapies. Antiandrogens offer an alternative mode of therapy for previously untreated patients with advanced prostatic cancer but have produced no convincing benefits in hormonally refractory patients.
多项临床试验表明，D期前列腺癌患者对抗雄激素药物的定性和定量反应与传统内分泌治疗的效果相似。这些抗雄激素药物总体上似乎是安全的，并且许多可以避免雌激素治疗中出现的心血管或血栓栓塞并发症风险增加的问题。此外，氟他胺对性欲和性功能的不良影响似乎比其他替代疗法要小。抗雄激素药物为先前未经治疗的晚期前列腺癌患者提供了一种替代治疗方式，但对激素难治性患者并未产生令人信服的益处。
